# Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

> **NCT00992537** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 27 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin degludec/insulin aspart
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT00992537
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2013-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992537, "Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00992537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*